- This topic is empty.
-
Posts
-
Kexing Biopharm’s anti-tumor product, Apexelsin® (Paclitaxel for injection,albumin-bound)has made new progress in its international expansion .It has been officially approved for marketing in the Dominican Republic, marking a further expansion of its global market access footprint in North America.
Albumin-bound paclitaxel formulation is widely recognized for its clinical advantages in oncology treatment. Compared with conventional paclitaxel injections and paclitaxel liposomal formulations, it offers improved safety profiles and better patient compliance. As a result, it has gained strong clinical acceptance and plays an important role in the treatment of various cancers.
According to data from Huajing Industry Research Institute, the global market size for albumin-bound paclitaxel reached approximately USD 2.6 billion in 2024. With the acceleration of global population aging and the rising incidence of solid tumors such as breast cancer and non-small cell lung cancer, the clinical demand and application prospects for this therapy continue to expand.
Since obtaining approval in the European Union in 2024, Kexing Biopharm has been steadily advancing the international registration of Apexelsin®, with approvals now secured in around 30 countries across Europe, Latin America, and other regions. The recent approval in the Dominican Republic further validates the product’s clinical and commercial value in oncology treatment and represents another meaningful achievement in Kexing Biopharm’s globalization strategy, particularly in strengthening its presence in the North American region.
https://www.kexingbiopharm.com/about.html
Kexing Biopharm
- You must be logged in to reply to this topic.